Haleon PLC Haleon plc: EMTN bond offering

RNS Number : 8576D

Haleon PLC

12 September 2024

 

 

 

Haleon plc: EMTN bond offering

 

12 September 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces that, on 11 September 2024, its wholly-owned subsidiary, Haleon UK Capital plc, successfully priced two notes under its Euro Medium Term Note ("EMTN") programme (the "Offering"). The Offering is expected to close on 18 September 2024, subject to customary closing conditions.

 

The Offering consisted of the following notes, issued by Haleon UK Capital plc and fully and unconditionally guaranteed by the Company:

 

·      €750,000,000 of fixed rate notes with a coupon of 2.875% maturing on 18 September 2028; and

 

·      £300,000,000 of fixed rate notes with a coupon of 4.625% maturing on 18 September 2033 (together, the "Notes")

 

The Company expects to use the net proceeds of the Offering for general corporate purposes including partial repayment of the $1.75bn bond maturing in March 2025.

 

Barclays, Bank of America, BNP Paribas and JP Morgan acted as joint book-running managers on the transaction.

 

The Notes will be issued under Haleon UK Capital plc's and Haleon Netherlands Capital B.V.'s £10,000,000,000 EMTN programme and admitted to trading on the International Securities Market of the London Stock Exchange.

 

The Notes have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration.

 

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the Notes described herein, nor shall there be any sale of these Notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

 

 

Amanda Mellor 

Company Secretary 

 

 

Enquiries

 

Investors		Media
Sonya Ghobrial	[phone]	Zoë Bird	[phone]
Rakesh Patel	[phone]	Gemma Thomas	[phone]
Emma White	[phone]
Email: [e-mail]		Email: [e-mail]

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com. 

 

 

                        

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

IODLBMLTMTABBFI